Adverum Biotechnologies Inc (OQ:ADVM)

May 03, 2024 08:00 am ET
Adverum Biotechnologies to Participate in Upcoming May Investor Conferences
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the following upcoming...
Apr 25, 2024 04:05 pm ET
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present the 26-week landmark interim...
Mar 18, 2024 04:05 pm ET
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year 2023....
Feb 28, 2024 04:05 pm ET
Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive...
Feb 16, 2024 08:31 am ET
Thinking about buying stock in Adverum Biotechnologies, Roma Green Finance, Wah Fu Education, ESSA Pharma, or Science 37?
NEW YORK, Feb. 16, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADVM, ROMA, WAFU, EPIX, and SNCE.
Feb 12, 2024 08:00 am ET
Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive...
Feb 08, 2024 07:00 am ET
Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints – – Preliminary safety data...
Feb 06, 2024 08:31 am ET
Thinking about buying stock in Gorilla Technology, Li Auto, Osisko Mining, Adverum Biotechnologies, or Kingsoft Cloud?
NEW YORK, Feb. 6, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GRRR, LI, OBNNF, ADVM, and KC.
Feb 05, 2024 07:45 am ET
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that it has agreed to sell approximately 106.25 million...
Feb 01, 2024 05:30 pm ET
Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review preliminary...
Jan 29, 2024 08:00 am ET
Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Romuald “Romu” Corbau, Ph.D., has joined Adverum as the...
Dec 07, 2023 04:05 pm ET
Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the initial LUNA preliminary efficacy and safety data will be...
Nov 28, 2023 04:05 pm ET
Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Linda Rubinstein, chief financial officer, and Star...
Nov 09, 2023 04:05 pm ET
Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the third quarter ended September 30,...
Nov 06, 2023 08:00 am ET
Adverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board of Directors
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the appointment of C. David Nicholson, Ph.D., as an...
Nov 04, 2023 05:54 pm ET
Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced updated data from the OPTIC extension study of patients with...
Sep 26, 2023 04:05 pm ET
Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 Trial
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced initial aflibercept protein expression data from its ongoing...
Sep 21, 2023 04:05 pm ET
Adverum Biotechnologies to Participate in Upcoming Investor Conferences
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Adverum Biotechnologies will present at the following...
Sep 05, 2023 04:05 pm ET
Adverum Biotechnologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Linda Rubinstein, chief financial officer of Adverum...
Aug 21, 2023 04:05 pm ET
Adverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as Chief Technology Officer
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that R. Andrew “Andy” Ramelmeier, Ph.D., has joined Adverum...
Aug 14, 2023 08:00 am ET
Adverum Biotechnologies to Participate in the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive...
Aug 10, 2023 04:05 pm ET
Adverum Biotechnologies Completes Enrollment of Phase 2 LUNA Trial in Wet AMD and Reports Second Quarter 2023 Financial Results
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today provided an update on its ongoing Phase 2 LUNA trial evaluating...
Jun 12, 2023 08:00 am ET
Adverum Biotechnologies Grants License to Ray Therapeutics Inc. for the AAV.7m8 Intravitreal Capsid
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, announces an agreement granting Ray Therapeutics a non-exclusive, royalty...
Jun 02, 2023 08:00 am ET
Adverum Biotechnologies to Participate in the Jefferies Healthcare Conference
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive...
May 25, 2023 06:30 am ET
Adverum Biotechnologies Announces New Executive Leadership Roles
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced new executive leadership roles that support the ongoing...
May 18, 2023 09:00 am ET
Adverum Biotechnologies Introduces an Intravitreal Gene Therapy Program for Geographic Atrophy and Presents Data on Its Ocular Gene Therapy Platform
Presented data on an optogenetics program utilizing an engineered melanopsin mutant that could serve as a therapeutic transgene for optogenetic vision restoration in indications with photoreceptor loss such as advanced GA, among others - -...
May 18, 2023 09:00 am ET
Adverum Biotechnologies Presents Nonclinical Data in Support of Ixo-vec’s Phase 2 Clinical Development at ASGCT 2023 Annual Meeting
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced new nonclinical data supporting the use of ixoberogene...
May 11, 2023 04:05 pm ET
Adverum Biotechnologies Reports First Quarter 2023 Financial Results
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the first quarter ended March 31, 2023...
May 10, 2023 04:05 pm ET
Adverum Biotechnologies to Participate in RBC Capital Markets Global Healthcare Conference
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that members of the executive team will participate in a...
May 02, 2023 04:30 pm ET
Adverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2023 including Data on a New Intravitreal (IVT) Geographic Atrophy Secondary to Dry AMD
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced new data will be presented during the American Society of...
Apr 23, 2023 01:00 pm ET
Adverum Biotechnologies Presents Nonclinical Data at the 2023 ARVO Annual Meeting Supporting Potential for Staggered Bilateral Administration of Ixo-vec
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced nonclinical data supporting the two doses of ixoberogene...
Apr 18, 2023 08:00 am ET
Adverum Biotechnologies Granted Innovative Licensing and Access Pathway Designation in the United Kingdom for Ixo-vec for the Treatment of Wet AMD
REDWOOD CITY, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced...
Apr 17, 2023 04:05 pm ET
Adverum Biotechnologies Announces Upcoming Nonclinical Data Presentation Supporting Staggered Bilateral Administration of Ixoberogene Soroparvovec (Ixo-vec) at the 2023 ARVO Annual Meeting
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present an abstract featuring...
Mar 30, 2023 04:05 pm ET
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Phase 2 LUNA Trial Update
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year ended...
Feb 27, 2023 04:05 pm ET
Adverum Biotechnologies to Present at Upcoming Investor Conferences
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive...
Jan 18, 2023 04:05 pm ET
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, announced a grant of stock options to a new employee. On January 17, 2023,...
Dec 06, 2022 04:05 pm ET
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, announced a grant of stock options to a new employee. On December 1, 2022,...
Nov 10, 2022 04:05 pm ET
Adverum Biotechnologies Reports Third Quarter 2022 Financial Results
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced financial results for the third quarter ended September 30,...
Nov 04, 2022 12:08 pm ET
Adverum Biotechnologies Presents Positive End of Study Results from the OPTIC Trial in Wet AMD Including Two-Year Outcomes Following a Single Intravitreal Injection of Ixo-vec (ADVM-022)
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced long-term follow-up data from the OPTIC study treating wet...
Oct 27, 2022 04:05 pm ET
Adverum Biotechnologies Announces Upcoming Data Presentation at The Retina Society Annual Meeting
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that new data from the OPTIC trial of ixoberogene...
Sep 30, 2022 04:45 pm ET
Adverum Biotechnologies Presents Anatomical Improvements in Intraretinal and Subretinal Fluid After a Single IVT Injection of Ixo-vec (ADVM-022) in the OPTIC Study in Wet AMD
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced new analyses from the OPTIC study treating wet age-related...
Sep 27, 2022 04:05 pm ET
Adverum Biotechnologies to Participate in the Chardan 6th Annual Genetic Medicines Conference
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Richard Beckman, M.D., chief medical officer of Adverum...
Sep 23, 2022 04:05 pm ET
Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Peter Soparkar, chief operating officer of Adverum...
Sep 23, 2022 08:00 am ET
Adverum Biotechnologies Announces Upcoming Data Presentation at AAO 2022
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that data from the OPTIC trial of ixoberogene soroparvovec...
Sep 14, 2022 08:00 am ET
Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet Age-Related Macular Degeneration
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the first subject was dosed in the LUNA Phase 2 trial...
Sep 08, 2022 04:05 pm ET
Adverum Biotechnologies to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive...
Aug 26, 2022 04:05 pm ET
Adverum to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive...
Aug 11, 2022 04:05 pm ET
Adverum Biotechnologies Reports Second Quarter 2022 Financial Results
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced financial results for the second quarter ended June 30,...
Aug 10, 2022 04:05 pm ET
Adverum Biotechnologies to Participate in the 2nd Annual H.C. Wainwright Ophthalmology Virtual Conference
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive...
Aug 01, 2022 04:05 pm ET
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced a grant of stock options to a new employee. On August 1,...
Jul 15, 2022 08:32 am ET
Adverum Biotechnologies Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After a Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in Wet AMD
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced new data from the OPTIC study treating wet age-related...
Jul 08, 2022 08:00 am ET
Adverum Biotechnologies Announces Upcoming Data Presentation at ASRS 2022
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that new data from the Phase 1 OPTIC study of ADVM-022...
Jul 06, 2022 04:05 pm ET
Adverum Biotechnologies Completes IND Amendment and Prepares to Initiate the Phase 2 LUNA Trial of ADVM-022 in Wet AMD
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that it has completed its Investigational New Drug (IND)...
Jun 24, 2022 08:00 am ET
Adverum Biotechnologies Granted Priority Medicines (PRIME) Designation by European Medicines Agency for ADVM-022 in Wet AMD
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the European Medicines Agency (EMA) has granted ADVM-022 Priority Medicines (PRIME)...
Jun 09, 2022 08:00 am ET
Adverum Biotechnologies Presents Three-Year Aflibercept Protein Expression and Improvement in Anatomic Outcomes After a Single IVT Injection of ADVM-022 in the OPTIC Study in Wet AMD
New data highlight ADVM-022 reductions in mean annualized anti-VEGF injections range from 81% in all OPTIC subjects to 93% in subjects with neutralizing antibody titers
Jun 02, 2022 04:05 pm ET
Adverum Biotechnologies Announces New Data at the Macula Society’s 2022 Annual Meeting
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced new data from the Phase 1 OPTIC study ADVM-022 (AAV.7m8-aflibercept) development program...
May 19, 2022 08:00 am ET
Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene Therapy
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today will announce new research pipeline data supporting the utility of its proprietary adeno-associated...
May 17, 2022 04:05 pm ET
Adverum Presents Data at ASGCT Further Supporting Phase 2 Development Plans for ADVM-022
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today will announce new data from the ADVM-022 development program in wet age-related macular...
May 12, 2022 04:05 pm ET
Adverum Biotechnologies Reports First Quarter 2022 Financial Results
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the first quarter ended March 31, 2022. “We remain on track to...
May 09, 2022 04:05 pm ET
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced a grant of stock options to a new employee. On May 9, 2022, Adverum granted a new...
May 02, 2022 04:30 pm ET
Adverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2022
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced new data will be presented during the American Society of Gene & Cell Therapy (ASGCT)...
May 01, 2022 02:15 pm ET
Adverum Biotechnologies Presents Additional Efficacy and Safety Data from the OPTIC Trial of ADVM-022 in Wet AMD at the ARVO 2022 Annual Meeting
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of new post-hoc analysis from the OPTIC study of ADVM-022 in wet...
Apr 19, 2022 06:00 pm ET
Adverum Biotechnologies Announces Upcoming Data Presentations at ARVO 2022
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that new data from the Phase 1 OPTIC study of ADVM-022 (AAV.7m8-aflibercept) in wet...
Apr 06, 2022 04:05 pm ET
Adverum Biotechnologies Proceeds with IND Amendment for ADVM-022 Phase 2 Trial in Wet AMD After Receiving Requested Type C Meeting Feedback from the FDA
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it has received feedback via a Type C meeting written response from the U.S. Food...
Mar 29, 2022 04:05 pm ET
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial Results
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021 and...
Mar 17, 2022 04:05 pm ET
Adverum Appoints Rabia Gurses Ozden, M.D. and Soo J. Hong, M.B.A., to Board of Directors
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Rabia Gurses Ozden, M.D. and Soo J. Hong, M.B.A., as independent...
Feb 28, 2022 08:00 am ET
Adverum Biotechnologies to Participate in the 42nd Annual Cowen Healthcare Conference
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum...
Feb 07, 2022 04:05 pm ET
Adverum Biotechnologies Appoints Richard Beckman M.D. as Chief Medical Officer
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Richard Beckman, M.D., has joined Adverum as the company’s chief medical officer...
Jan 12, 2022 07:35 am ET
Thinking about buying stock in Jaguar Health, Evofem Biosciences, Adverum Biotechnologies, FREYR Battery, or Planet Labs?
NEW YORK, Jan. 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JAGX, EVFM, ADVM, FREY, and PL.
Jan 06, 2022 04:05 pm ET
Adverum Biotechnologies Appoints Star Seyedkazemi, Pharm.D. as Chief Development Officer
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Star Seyedkazemi, Pharm.D., joined Adverum as the company’s chief development...
Jan 04, 2022 08:00 am ET
Adverum Biotechnologies Granted Orphan Drug Designation by FDA for Gene Therapy Candidate in Preclinical Development for the Treatment of Blue Cone Monochromacy
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ADVM-062...
Dec 21, 2021 08:00 am ET
Adverum Biotechnologies Provides ADVM-022 Development Update and Anticipated Corporate Milestones for 2022
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the completion of a review of its ADVM-022 program, outlined plans for the next stage of...
Dec 06, 2021 09:00 am ET
Adverum Biotechnologies Appoints Rupert D’Souza, Ph.D., M.B.A. as Chief Financial Officer
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Rupert D’Souza, Ph.D., M.B.A., has joined Adverum as the company’s chief financial...
Nov 04, 2021 04:05 pm ET
Adverum Reports Third Quarter 2021 Results
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the third quarter ending September 30, 2021 and provided a business...
Oct 09, 2021 11:17 am ET
Adverum Presents Clinical Data on ADVM-022 at the American Society of Retina Specialists 39th Annual Scientific Meeting
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today is presenting data from the INFINITY clinical trial of ADVM-022 in patients with diabetic macular...
Oct 04, 2021 08:30 am ET
Thinking about buying stock in OpGen, Adverum Biotechnologies, OraSure Technologies, Sonnet BioTherapeutics, or Sio Gene Therapies?
NEW YORK, Oct. 4, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OPGN, ADVM, OSUR, SONN, and SIOX.
Oct 01, 2021 04:00 pm ET
Adverum Presents 2-Year OPTIC Data Demonstrating Sustained Durability and Promising Safety Profile from Single Intravitreal Injection of ADVM-022 in Wet AMD Patients Who Previously Required Frequent A
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced new long-term data from the OPTIC clinical trial of ADVM-022 single, in-office...
Sep 27, 2021 09:00 am ET
Adverum to Present Data from ADVM-022 Clinical Trials at Upcoming Medical Conferences
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of new clinical data on ADVM-022 intravitreal (IVT) injection gene...
Aug 23, 2021 09:00 am ET
Adverum Appoints Global Regulatory Leader Jim Wang, Ph.D., as Senior Vice President, Head of Regulatory Affairs
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Jim Wang, Ph.D., has been appointed senior vice president, head of regulatory...
Aug 05, 2021 04:05 pm ET
Adverum Reports Second Quarter 2021 Results
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the second quarter ended June 30, 2021. “Adverum has an experienced...
Jul 22, 2021 04:05 pm ET
Adverum Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today provided an update on the ADVM-022 development program following a thorough review of data...
Jul 01, 2021 08:00 am ET
Adverum Announces Appointment of Jon Williams, Ph.D., as Vice President, Clinical Affairs
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Jon Williams, Ph.D., as vice president, clinical affairs, effective...
Jun 24, 2021 04:05 pm ET
Adverum Announces Changes to Management Team
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Leone Patterson, president and chief financial officer, has resigned to pursue...
Jun 01, 2021 08:00 am ET
Adverum Appoints CMO and CSO
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of two highly experienced leaders, Julie Clark, M.D., as chief medical...
May 12, 2021 03:17 pm ET
The Sonic Fund II, L.P. Comments on Preliminary Voting Results of Adverum Annual Meeting
The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or “Adverum”), today issued the following statement regarding the preliminary voting results from the Company’s 2021 Annual Meeting of Stockholders (the “2021 Annual Meeting”).
May 12, 2021 01:05 pm ET
Adverum Stockholders Re-Elect All Adverum Director Nominees at 2021 Annual Meeting
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that, based on a preliminary vote count provided by its proxy solicitors following its...
May 11, 2021 03:15 pm ET
The Sonic Fund II, L.P. Issues Statement to Adverum Stockholders
The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or “Adverum”), today issued the following statement regarding the Company’s upcoming 2021 Annual Meeting of Stockholders (the “2021 Annual Meeting”), which will be held on Wednesday, May 12, 2021.
May 10, 2021 10:41 am ET
The Sonic Fund II, L.P. Reminds Adverum Stockholders to Vote for Its Three Independent Director Nominees at May 12 Annual Meeting
The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or “Adverum”), today reminded stockholders to make their voices heard at the Company’s upcoming 2021 Annual Meeting of Stockholders (the “2021 Annual Meeting”), which will be held on Wednesday, May 12, 2021.
May 10, 2021 08:15 am ET
Adverum Issues Statement Regarding Upcoming Annual Meeting of Stockholders
Adverum Biotechnologies Inc. (“Adverum”) (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today issued the following statement regarding the Annual Meeting of Stockholders (“Annual...
May 06, 2021 04:00 pm ET
Adverum Reports First Quarter 2021 Results
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the first quarter ended March 31, 2021. “Our management team and...
May 06, 2021 09:48 am ET
Glass Lewis Joins ISS In Recommending Adverum Shareholders Vote for All Three Independent Sonic Director Nominees
The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or “Adverum”), today announced that leading proxy advisory firm Glass, Lewis & Co., LLC (“Glass Lewis”) has joined Institutional Shareholder Services Inc. (“ISS”) in recommending that Adverum stockholders vote FOR the election of Sonic’s three independent, highly qualified nominees (the “Nominees”) – Jean Bennett, Jodi Cook and Herbert Hughes – for election to the Company’s Board of Directors (the “Board”) at the upcoming 2
May 04, 2021 08:30 am ET
ISS Recommends Adverum Stockholders Vote to Elect Sonic’s Three Independent, Highly Qualified Nominees
The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or “Adverum”), today announced that leading proxy advisory firm Institutional Shareholder Services Inc. (“ISS”), recommended that stockholders vote on the GREEN proxy card FOR Sonic’s three independent, highly qualified nominees (the “Nominees”) – Jean Bennett, Jodi Cook and Herbert Hughes – for election to the Company’s Board of Directors (the “Board”) at the upcoming 2021 Annual Meeting of Stockholders (the “2021 Annual M
May 01, 2021 03:25 pm ET
Adverum Biotechnologies Presents Long-term Data through March 10, 2021 from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy in Treatment-experienced Wet AMD Patients at ARVO 2021
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced new long-term data from the OPTIC clinical trial of ADVM-022 single intravitreal (IVT)...
Apr 29, 2021 02:58 pm ET
The Sonic Fund II, L.P. Comments on Adverum Biotechnologies Update Regarding INFINITY Phase 2 Trial of ADVM-022
The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or “Adverum”), today commented on the Company’s April 28 announcement of a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema (DME):
Apr 28, 2021 04:01 pm ET
Adverum Biotechnologies Provides Update on the INFINITY Trial Evaluating ADVM-022 in Patients with Diabetic Macular Edema
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant decrease in ocular pressure) in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the...
Apr 26, 2021 09:00 am ET
The Sonic Fund II, L.P. Issues Presentation Correcting Adverum’s Misstatements
The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or “Adverum”), today issued a supplemental presentation detailing – and correcting – a number of the Company’s recent misstatements. Sonic has nominated three independent, highly qualified director candidates – Jean Bennett, Jodi Cook and Herbert Hughes (the “Nominees”) – for election to the Adverum Board of Directors (the “Board”) at the 2021 Annual Meeting of Stockholders (the “2021 Annual Meeting”).
Apr 22, 2021 05:00 pm ET
The Sonic Fund II, L.P. Issues Presentation Detailing Compelling Case for Immediate Board Upgrade at Adverum Biotechnologies, Inc.
The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or “Adverum”), today issued an investor presentation detailing the case for an improved Board at Adverum to better position the Company for success. Sonic has nominated three independent, highly qualified director candidates – Jean Bennett, Jodi Cook and Herbert Hughes (the “Nominees”) – for election to the Adverum Board of Directors (the “Board”) at the 2021 Annual Meeting of Stockholders (the “2021 Annual Meeting”).
Apr 22, 2021 04:15 pm ET
Adverum Files Investor Presentation Highlighting Significant Strategic Progress and Purpose-Built Board to Oversee Stockholder Value Creation
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it has filed a new investor presentation with the U.S. Securities and Exchange...
Apr 21, 2021 08:00 am ET
Adverum Mails Letter to Stockholders Highlighting World-Class Board of Directors Overseeing Successful ADVM-022 Commercial Launch
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it is mailing a letter to stockholders in connection with its 2021 Annual Meeting of...
Apr 19, 2021 04:10 pm ET
The Sonic Fund II, L.P. Files Definitive Proxy Statement and Sends Letter to Stockholders of Adverum Biotechnologies, Inc.
The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or “Adverum”), announced today that it has filed a definitive proxy statement and GREEN proxy card with the SEC in conjunction with the 2021 Annual Meeting of Stockholders (the “2021 Annual Meeting”) that the Company is rushing to hold on May 12, 2021. Sonic has nominated three independent, highly qualified director candidates – Jean Bennett, Jodi Cook and Herbert Hughes (the “Nominees”) – for election to the Adverum
Apr 16, 2021 08:05 am ET
Adverum Biotechnologies to Present New Data from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at ARVO 2021 
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of additional clinical data for Cohorts 1-4 in the OPTIC clinical trial...
Apr 15, 2021 08:00 am ET
Adverum Files Definitive Proxy Materials and Mails Letter to Stockholders Detailing Strength of Team and Acceleration Toward Commercialization of ADVM-022
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange...
Mar 30, 2021 09:00 am ET
Adverum Announces Senior Appointments for Patient Access and Clinical Operations as ADVM-022 Advances Toward Global Phase 3 Trials
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of two experienced professionals to support its patient advocacy...
Mar 18, 2021 04:00 pm ET
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced a grant of stock options to a new employee. On March 15, 2021, the company granted the...
Mar 17, 2021 05:10 pm ET
Adverum Announces Board Slate for 2021 Annual Meeting and Reiterates Commitment to Stockholder Value Creation
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that its Board of Directors is expected to nominate a Board slate consisting of three...
Mar 01, 2021 04:00 pm ET
Adverum Announces Shortened Timelines and Clear Development Path for ADVM-022 Intravitreal Gene Therapy in Wet AMD, Reports Recent Business Progress and Fourth Quarter 2020 Financial Results
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it has gained alignment with the U.S. Food and Drug Administration (FDA) on the...
Feb 22, 2021 04:00 pm ET
Adverum to Host Conference Call and Webcast to Highlight Updated ADVM-022 Development Plans in Wet AMD, Recent Business Progress, and Fourth Quarter 2020 Financial Results
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it will host a conference call and webcast on Monday, March 1, 2021 at 1:30 pm...
Feb 22, 2021 09:00 am ET
Adverum Appoints Esteemed Healthcare Executive Reed V. Tuckson, M.D., to Board of Directors
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Reed V. Tuckson, M.D., FACP as an independent member of Adverum’s...
Feb 18, 2021 04:00 pm ET
Adverum Appoints Christopher J. DeRespino as Chief Business Officer
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Christopher J. DeRespino as chief business officer, effective...
Feb 10, 2021 04:48 pm ET
Adverum to Present Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD at the Angiogenesis, Exudation, and Degeneration 2021 Virtual Meeting
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of data from Cohorts 1-4 of the OPTIC Phase 1 clinical trial of ADVM-022...
Feb 02, 2021 09:00 am ET
Adverum Biotechnologies Announces Publication of Preclinical Long-Term Safety Data on ADVM-022 IVT Gene Therapy
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the publication of preclinical data on ADVM-022 intravitreal (IVT) gene therapy in...
Jan 11, 2021 08:00 am ET
Adverum Biotechnologies Completes Patient Enrollment for INFINITY Phase 2 Trial of ADVM-022 in DME and Provides 2021 Business Outlook
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the completion of patient enrollment in the INFINITY Phase 2 trial to evaluate a single...
Jan 07, 2021 11:57 am ET
Adverum Biotechnologies Announces New GMP Gene Therapy Manufacturing Facility
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced plans for a new Good Manufacturing Practices facility in Durham, North Carolina. Adverum...
Jan 05, 2021 09:00 am ET
Adverum Biotechnologies to Present at 39th Annual J.P. Morgan Healthcare Conference
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the company’s presentation at the 39th Annual J.P. Morgan Healthcare Conference on...
Dec 14, 2020 09:00 am ET
Adverum Biotechnologies Appoints Pharmaceutical Industry Veteran Dawn Svoronos to Board of Directors
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Dawn Svoronos as an independent member of Adverum’s Board of...
Nov 23, 2020 11:00 am ET
Adverum Biotechnologies Presents at the Piper Sandler Annual Virtual Healthcare Conference
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the company’s presentation at the Piper Sandler 32nd Annual Virtual Healthcare...
Nov 14, 2020 10:00 am ET
Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced positive new interim data from Cohorts 1-4 of the OPTIC Phase 1 clinical trial of...
Nov 05, 2020 04:01 pm ET
Adverum Biotechnologies Reports Recent Business Progress and Third Quarter 2020 Financial Results
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported recent business progress and financial results for the third quarter ended September 30,...
Oct 20, 2020 09:00 am ET
Adverum Biotechnologies to Present New Data from the OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at AAO 2020 Virtual
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of additional clinical data for Cohorts 1-4 in the OPTIC Phase 1...
Sep 15, 2020 08:00 am ET
Adverum Biotechnologies Announces Appointment of Christopher J. Morrison, Ph.D. as Vice President, Process Science
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Christopher J. Morrison, Ph.D. joined the company as vice president, process...
Sep 10, 2020 08:00 am ET
Adverum Biotechnologies to Participate in the Cantor Virtual Global Healthcare Conference
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the company will present at the Cantor Virtual Global Healthcare Conference on...
Aug 18, 2020 09:00 am ET
Adverum Biotechnologies Announces Closing of $217 Million Public Offering of Common Stock
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the closing of its previously announced underwritten public offering of 16,675,000 shares...
Aug 12, 2020 09:37 pm ET
Adverum Biotechnologies Announces Pricing of Public Offering of Common Stock
Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the pricing of its underwritten public offering of 14,500,000 shares of its common stock...
Aug 11, 2020 04:01 pm ET
Adverum Biotechnologies Announces $200 Million Public Offering of Common Stock
Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it has commenced an underwritten public offering of $200 million of its common stock....
Aug 10, 2020 04:00 pm ET
Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for wet AMD, Reports Recent Business Progress and Second Quarter
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced positive new interim data from Cohorts 1-4 of the OPTIC Phase 1 clinical trial of...
Jul 29, 2020 04:05 pm ET
Adverum Biotechnologies to Host a Conference Call and Webcast to Report Second Quarter 2020 Financial Results and Provide Corporate Update
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it will host a conference call and webcast on Monday, August 10, 2020 at 1:30 pm...
Jul 21, 2020 08:00 am ET
Adverum Biotechnologies Announces Appointment of Thomas Kochy as Vice President, Commercial and Program Strategy
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Thomas Kochy joined the company as vice president, commercial and program strategy....
Jul 13, 2020 08:30 am ET
Adverum Biotechnologies Announces First Patient Randomized in Phase 2 INFINITY Trial of ADVM-022 Single Injection Gene Therapy for Diabetic Macular Edema (DME)
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the first patient was randomized in the INFINITY clinical trial to evaluate ADVM-022...
Jul 06, 2020 09:00 am ET
Adverum Biotechnologies Announces Completion of Patient Dosing in Cohort 4 of the OPTIC Phase 1 Trial of ADVM-022 Single Injection Gene Therapy for Wet AMD
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the completion of patient dosing in Cohort 4 of OPTIC, a Phase 1 clinical trial,...
Jun 25, 2020 04:01 pm ET
Adverum Biotechnologies Announces Appointment of Heikki Jouttijärvi as Vice President of Manufacturing
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Heikki Jouttijärvi joined the company as vice president, manufacturing. In this...
Jun 15, 2020 04:01 pm ET
Adverum Biotechnologies Announces Leadership Transition
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Laurent Fischer, M.D. has joined the company as its chief executive officer and a...
Jun 04, 2020 04:05 pm ET
Adverum Biotechnologies to Participate in Goldman Sachs 41st Annual Global Healthcare Conference
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the company will present at the Goldman Sachs 41st Annual Global Healthcare...
May 28, 2020 04:01 pm ET
Adverum Biotechnologies Announces New INFINITY Phase 2 Trial for ADVM-022 in Diabetic Macular Edema, Reports Recent Business Progress and First Quarter 2020 Financial Results
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the initiation of INFINITY, a Phase 2,  multi-center, randomized, double-masked, active...
May 21, 2020 04:05 pm ET
Adverum Biotechnologies to Host a Conference Call and Webcast to Report First Quarter 2020 Financial Results and Provide Corporate Update
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it will host a conference call and audio webcast on Thursday, May 28, 2020 at 1:30...
May 04, 2020 05:10 pm ET
Adverum Biotechnologies Reports Positive Interim Data from Cohorts 1-3 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced new interim clinical data from Cohorts 1-3 of the OPTIC Phase 1 dose-ranging clinical...
Apr 30, 2020 04:05 pm ET
Adverum Biotechnologies Announces Virtual Presentations of Data through ASGCT and ARVO
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced several virtual presentations of data from the company’s gene therapy programs in May...
Apr 27, 2020 04:01 pm ET
Adverum Biotechnologies to Host a Conference Call and Webcast to Present New Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the Company will host a conference call and webcast to present new data from the OPTIC...
Apr 27, 2020 08:00 am ET
Adverum Biotechnologies Doses First Patient in Cohort 4 of OPTIC Phase 1 Clinical Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the first patient was dosed in Cohort 4 of the ongoing OPTIC Phase 1 clinical trial...
Apr 20, 2020 04:05 pm ET
Adverum Biotechnologies Appoints Ophthalmology Industry Veteran Scott Whitcup, M.D. to Board of Directors
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Scott Whitcup, M.D. to the Company’s Board of Directors. “We are...
Mar 12, 2020 04:01 pm ET
Adverum Biotechnologies Reports Recent Business Progress and Fourth Quarter 2019 Financial Results
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the fourth quarter ended December 31, 2019 and provided a corporate...
Mar 11, 2020 04:38 pm ET
Adverum Biotechnologies Announces Data Presentations at ARVO 2020
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced presentations on the company’s gene therapy programs to be presented at the Association...
Mar 05, 2020 04:01 pm ET
Adverum Biotechnologies to Host a Conference Call and Webcast to Report Fourth Quarter 2019 Financial Results and Provide Corporate Update
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it will host a conference call and audio webcast on Thursday, March 12, 2020 at 1:30...
Mar 04, 2020 04:25 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adverum Biotechnologies, Inc. – ADVM
Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. (“Adverum” or the “Company”) (NASDAQ: ADVM). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Feb 26, 2020 09:30 am ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Adverum Biotechnologies, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. (“Adverum” or “the Company”) (NASDAQ:
Feb 25, 2020 12:26 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adverum Biotechnologies, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. (“Adverum” or “the Company”) (NASDAQ:
Feb 25, 2020 10:00 am ET
ADVM INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Adverum Biotechnologies, Inc.
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Adverum Biotechnologies, Inc. (“Adverum” or the “Company”) (NASDAQ: ADVM) Such investors are encouraged to obtain additional...
Feb 25, 2020 08:00 am ET
Adverum Biotechnologies Appoints Angela Thedinga as Chief Technology Officer
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Angela Thedinga has been promoted to chief technology officer. Ms. Thedinga joined...
Feb 24, 2020 05:31 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc.  (“Adverum” or the “Company”) (NASDAQ: ADVM).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529,...
Feb 19, 2020 04:01 pm ET
Adverum Biotechnologies to Present at Upcoming Investor Conferences
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the company will present at two upcoming investor conferences: Investor Presentation:...
Feb 14, 2020 04:01 pm ET
Adverum Biotechnologies Announces Closing of $150 Million Public Offering of Common Stock
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the closing of its previously announced underwritten public offering of 10,925,000 shares...
Feb 11, 2020 08:27 pm ET
Adverum Biotechnologies Announces Pricing of Public Offering of Common Stock
Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the pricing of its underwritten public offering of 9,500,000 shares of its common stock at...
Feb 10, 2020 04:01 pm ET
Adverum Biotechnologies Announces $100 Million Public Offering of Common Stock
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it has commenced an underwritten public offering of $100 million of its common...
Feb 08, 2020 03:06 pm ET
Adverum Biotechnologies Reports New Interim Data from Cohorts 1 and 2 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at Angiogenesis, Exudation, and Degeneration 2020
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced new interim clinical data from the OPTIC Phase 1 dose-ranging clinical trial of ADVM-022...
Jan 28, 2020 04:02 pm ET
Adverum Biotechnologies to Present Additional Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD at the Angiogenesis, Exudation, and Degeneration 2020 Meeting
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of 24-week data from the second cohort of patients (n=6; 2 x 1011...
Jan 27, 2020 04:00 pm ET
Adverum Biotechnologies Moves to New Headquarters and Expands Laboratory Space in Redwood City, CA
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the opening of its new corporate headquarters, located at 800 Saginaw Drive in Redwood...
Jan 12, 2020 06:00 pm ET
Adverum Biotechnologies Reports Continued Momentum with OPTIC Trial for ADVM-022 Intravitreal Gene Therapy in Wet AMD and Provides 2020 Outlook
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reviewed recent business and development progress and provided an outlook for 2020. “In 2019, we...
Jan 11, 2020 12:05 pm ET
Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the Atlantic Coast Retina Club Macula 20/20 Annua
Zero anti-VEGF rescue injections required following intravitreal ADVM-022; First patient has reached 52-weeks post treatment----Vision remains stable and anatomical improvements maintained-- MENLO PARK, Calif., Jan. 11, 2020 (GLOBE NEWSWIRE) --...
Dec 18, 2019 04:01 pm ET
Adverum Biotechnologies to Present at Upcoming Conferences
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the company will present at upcoming conferences: Investor Presentation: 38th Annual...
Dec 02, 2019 10:53 am ET
Shareholder Alert - Adverum Biotechnologies - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
Kehoe Law Firm, P.C. continues to investigate potential securities claims on behalf of investors of Adverum Biotechnologies (“Adverum” or the “Company”) (NasdaqGS: ADVM) concerning possible violations of the federal securities laws. Investors of...
Nov 20, 2019 04:01 pm ET
Adverum Biotechnologies to Participate in Piper Jaffray’s 31st Annual Healthcare Conference
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that  the company will present at Piper Jaffray’s 31st Annual Healthcare Conference on...
Nov 11, 2019 10:50 am ET
Adverum Biotechnologies Shareholder Alert – Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Adverum Biotechnologies (“Adverum” or the “Company”) (NasdaqGS: ADVM) concerning possible violations of the federal securities laws. Investors of Adverum...
Nov 07, 2019 04:01 pm ET
Adverum Biotechnologies Reports Recent Business Progress and Third Quarter 2019 Financial Results
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the third quarter ended September 30, 2019 and provided a corporate...
Oct 31, 2019 04:01 pm ET
Adverum Biotechnologies to Host a Conference Call and Webcast to Report Third Quarter 2019 Financial Results and Provide Corporate Updates
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced today announced that it will host a conference call and audio webcast on Thursday,...
Oct 30, 2019 04:01 pm ET
Adverum Biotechnologies Expands Leadership Team with the Appointment of Peter Soparkar as Chief Legal Officer
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of seasoned life sciences executive Peter Soparkar as chief legal...
Oct 24, 2019 08:00 am ET
Adverum Biotechnologies Doses First Patient in Third Cohort of OPTIC Phase 1 Clinical Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the first patient was dosed in the third cohort (n=9) of the ongoing OPTIC phase 1...
Oct 23, 2019 08:00 am ET
Adverum Biotechnologies Announces Data Presentations at the European Society of Gene and Cell Therapy (ESGCT) 2019 Congress
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced presentations on the company’s gene therapy programs to be presented at the European...
Oct 11, 2019 07:26 pm ET
Adverum Biotechnologies Reports Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at the American Academy of Ophthalmology 2019 Annual
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced additional clinical data for the first cohort of patients (n=6) in the ongoing OPTIC...
Sep 26, 2019 05:25 pm ET
Adverum Biotechnologies to Present Additional Clinical Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy to Treat Wet AMD at the American Academy of Ophthalmology 201
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced it will present additional clinical data for the first cohort of patients (n=6) in the...
Sep 12, 2019 02:41 am ET
Adverum Biotechnologies Reports Positive 24-Week Data from First Cohort of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy to Treat Wet AMD
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of positive 24-week clinical data from the first cohort of patients...
Sep 04, 2019 04:01 pm ET
Adverum Biotechnologies to Host a Conference Call and Webcast to Present 24-week Data from First Cohort of OPTIC Trial of ADVM-022 Intravitreal Injection Gene Therapy to Treat Wet AMD at Retina Societ
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of interim 24-week data from the first cohort of patients (n=6) in the...
Aug 28, 2019 04:01 pm ET
Adverum Biotechnologies to Present 24-Week Data from First Cohort of OPTIC Trial of ADVM-022 Intravitreal Injection Gene Therapy to Treat Wet AMD at the American Academy of Ophthalmology 2019 Annual M
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that 24-week data from the first cohort of patients (n=6) in the OPTIC phase 1 clinical...
Aug 08, 2019 04:00 pm ET
Adverum Biotechnologies Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the second quarter ended June 30, 2019 and provided a corporate...
Aug 01, 2019 04:00 pm ET
Adverum Biotechnologies Announces Board and Senior Management Changes
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today made several key personnel announcements. Board member and co-founder Mitchell Finer, Ph.D. is...
Jul 25, 2019 04:00 pm ET
Adverum Biotechnologies to Host a Conference Call and Webcast to Report Second Quarter 2019 Financial Results and Provide Corporate Updates
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular diseases, today announced that it will host a conference call and audio webcast on Thursday, August 8, 2019 at 1:30 PM...
Jul 15, 2019 04:00 pm ET
Adverum Biotechnologies Appoints Senior Leaders
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointments of Carol Hoang, Pharm.D., MBA, to the newly-created position of vice...
Jul 08, 2019 07:58 am ET
Adverum Biotechnologies to Present Data at Upcoming Conferences
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced presentations at the following upcoming conferences: Event: American Society of Virology...
Jun 10, 2019 09:00 am ET
Adverum Biotechnologies Doses First Patient in Second Cohort of OPTIC Phase 1 Clinical Trial of ADVM-022 Gene Therapy for Wet AMD
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the first patient was dosed in the second cohort of the ongoing OPTIC phase 1...
May 16, 2019 09:00 am ET
Adverum Biotechnologies Provides Update on OPTIC Phase 1 Trial for ADVM-022 in Wet AMD
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on ADVM-022...
May 08, 2019 04:00 pm ET
Adverum Biotechnologies Reports First Quarter 2019 Financial Results and Provides Corporate Update
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the first quarter ended March 31, 2019 and provided a corporate...
May 02, 2019 04:30 pm ET
Adverum Biotechnologies Announces Board Changes
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Rekha Hemrajani, M.B.A., James Scopa, J.D., M.B.A., and Mark Lupher,...
May 02, 2019 06:00 am ET
Adverum Biotechnologies to Present 30-month Preclinical Safety and Expression Data for ADVM-022 Gene Therapy in Wet AMD at the ASGCT 22nd Annual Meeting
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced new long-term safety and expression data out to 30 months following a single intravitreal...
Apr 30, 2019 01:30 pm ET
Adverum Biotechnologies Presents First Preclinical Data on Dosing Contralateral Eye with ADVM-022 Gene Therapy for Wet AMD at the ARVO 2019 Annual Meeting
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, presented today for the first time preclinical data on sequentially dosing a contralateral eye with...
Apr 24, 2019 04:00 pm ET
Adverum Biotechnologies Appoints Thomas Leung as Chief Financial Officer
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Thomas Leung as chief financial officer.  Mr. Leung will serve as a...
Apr 16, 2019 04:00 pm ET
Adverum Biotechnologies to Present New Preclinical Data on ADVM-022 Gene Therapy for Wet AMD at ASGCT and ARVO
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of new preclinical data at upcoming conferences, including the American...
Apr 15, 2019 09:00 am ET
Adverum Biotechnologies Provides Clinical Program Update on ADVM-022 Gene Therapy for Wet AMD
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today provided a program update on ADVM-022, a novel, single-administration gene therapy being evaluated...
Apr 08, 2019 09:26 am ET
Report: Developing Opportunities within Adverum Biotechnologies, Aurinia Pharmaceuticals, Baytex Energy, Limelight Networks, Park City Group, and HealthStream — Future Expectations, Projections Moving
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Adverum Biotechnologies, Inc. (NASDAQ:ADVM), Aurinia Pharmaceuticals Inc...
Apr 01, 2019 04:01 pm ET
Adverum Biotechnologies Appoints Ophthalmology Industry Veteran Aaron Osborne, MBBS MRCOphth, as Chief Medical Officer
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of Aaron Osborne, MBBS MRCOphth as chief medical officer, effective...
Mar 18, 2019 09:00 am ET
Adverum Biotechnologies to Participate in Upcoming Conferences
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the Company’s participation in several upcoming conferences: Event: Chardan’s In Vivo...
Mar 06, 2019 04:10 pm ET
Adverum Biotechnologies Reports Fourth Quarter 2018 Financial Results and Provides Corporate Update
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the fourth quarter ended December 31, 2018 and provided a corporate...
Feb 28, 2019 04:10 pm ET
Adverum to Present at the Cowen 39th Annual Health Care Conference
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the company will be participating in the upcoming Cowen 39th Annual Health Care...
Feb 13, 2019 04:10 pm ET
Adverum to Present at the 8th Annual SVB Leerink Global Healthcare Conference
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the company will be participating in the upcoming 8th Annual SVB Leerink Global...
Feb 11, 2019 08:30 am ET
Adverum Biotechnologies Announces Presentation of Preclinical Long-Term Safety Data of ADVM-022 at 2019 Angiogenesis, Exudation, and Degeneration Conference
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced non-human primate (NHP) long-term safety data of ADVM-022, an intravitreally delivered...
Jan 30, 2019 07:30 am ET
Report: Developing Opportunities within Waste Connections, Performance Food Group, HealthEquity, PS Business Parks, Adverum Biotechnologies, and Bellicum Pharmaceuticals — Future Expectations, Project
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Waste Connections, Inc. (NYSE:WCN), Performance Food Group Company...
Jan 06, 2019 08:00 pm ET
Adverum Biotechnologies Provides 2019 Outlook
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today reviewed recent progress and provided an outlook for 2019. “For our lead gene therapy...
Dec 20, 2018 08:30 am ET
Adverum to Present at the 37th Annual J.P. Morgan Healthcare Conference
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today announced the company will be participating in the upcoming 37th Annual J.P. Morgan...
Dec 03, 2018 04:10 pm ET
Adverum Biotechnologies Appoints Mike Fitzgerald as Vice President, Human Resources
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today announced the appointment of Mike Fitzgerald as vice president, human resources.  Mr....
Dec 03, 2018 08:30 am ET
Adverum Biotechnologies Announces Publication of Preclinical Long-Term Expression and Efficacy Data in Molecular Therapy
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today announced the publication of preclinical long-term expression and efficacy data in Molecular...
Nov 19, 2018 08:30 am ET
Adverum Announces First Patient Dosed in OPTIC Phase 1 Trial of ADVM-022 Gene Therapy in Wet Age-Related Macular Degeneration
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today announced that the first patient was dosed in the OPTIC phase 1 trial evaluating ADVM-022...
Nov 13, 2018 04:30 pm ET
Adverum to Present at 30th Annual Piper Jaffray Healthcare Conference
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today announced the company will be participating in the upcoming 30th Annual Piper Jaffray...
Nov 08, 2018 04:10 pm ET
Adverum Biotechnologies Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today reported financial results for the third quarter ended September 30, 2018 and provided a...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.